Core Insights - Quest Diagnostics (DGX) is scheduled to release its fourth-quarter 2025 results on February 10, with adjusted earnings per share (EPS) of $2.60 in the last reported quarter, exceeding the Zacks Consensus Estimate by 3.59% [2] - The Zacks Consensus Estimate for Q4 revenues is $2.75 billion, reflecting a 4.8% increase year-over-year, while EPS is expected to rise by 5.4% to $2.35 [3] Q4 Estimates - The revenue estimate for Quest Diagnostics indicates a growth of 4.8% compared to the previous year [3] - The EPS estimate suggests a 5.4% increase from the prior year [3] Estimate Revision Trend - Estimates for Quest Diagnostics' Q4 earnings have remained stable over the past 30 days, indicating consistent expectations leading up to the announcement [4] Factors Influencing Q4 Results - The core Diagnostics Information Services (DIS) business is anticipated to show strong revenue growth due to organic growth in physician, hospital, and consumer channels [5] - The acquisition of clinical testing assets from Fresenius Medical Care is expected to positively impact physician channel revenues, contributing an estimated 2.8% to DIS revenues in Q4 [6] Advanced Diagnostics Performance - Robust revenue generation is expected in Advanced Diagnostics across various clinical areas, including cardiometabolic, endocrine, and autoimmune disease testing [7] - Growth in Brain Health is likely driven by AD-detect blood tests for assessing Alzheimer's disease risk [7] Collaborative Lab Solutions - Collaborative Lab Solutions may have contributed to growth in the hospital channel, with strategic partnerships enhancing access to diagnostic innovations [8] Revenue Growth Drivers - An enhanced questhealth.com platform is likely to have supported strong fourth-quarter revenues through partnerships with consumer health brands [10] - The DIS revenues are projected to increase by 4.7% year-over-year in Q4 [11] Operational Excellence - The company is expected to have continued expanding automation, robotics, and AI to improve quality and productivity, contributing to top-line growth [12] Earnings ESP and Zacks Rank - Quest Diagnostics has an Earnings ESP of 0.00%, indicating no expected surprise in earnings [13] - The company currently holds a Zacks Rank of 2 (Buy) [14]